Conjugates of diverse APIs +/ - a biologic Target both intracellular and extracellular pathways High Drug Antibody Ratio (“DAR”) medicines Can include APIs with DAR of 10 up to >250 Tailored release of APIs Release of API payloads enabled by pH modulation or enzymatic cleavage of linkers Proven safety record of the ABC Platform >2,500 patient years of experience in patients and >13,00 tarcocimab injections Diverse APIs of varying biophysical properties are covalently embedded in the biopolymer and released over a designed - in time Any biologic can be conjugated to the biopolymer via a stable, site - specific linkage Engineered to make medicines last longer and extend their therapeutic benefit. Combines multiple APIs and can be tailored to meet a specific therapeutic goal. High molecular weight, optically clear and made of phosphorylcholine, the primary hydrophilic component of human cell membranes Drug Cargo Antibody or other Biologic Biopolymer A new combination of targeting, high drug loading, mixed API formats and tailored drug release – with applications in ophthalmic and systemic diseases Antibody Biopolymer Conjugate Drug (“ABCD”): A product platform enabling multi - mechanism therapies empowered for durability Kodiak’s ABCD Platform is designed f or targeted, high drug loading, multi - specific and tailored modulation of biological pathways 14